Edition:
United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

61.83USD
24 May 2019
Change (% chg)

$1.12 (+1.84%)
Prev Close
$60.71
Open
$61.14
Day's High
$62.07
Day's Low
$60.76
Volume
54,592
Avg. Vol
132,118
52-wk High
$65.55
52-wk Low
$29.17

Berman, Robert 

Mr. Robert Berman M.D., serves as Chief Medical Officer of Biohaven Pharmaceutical Holding Company Limited. Dr. Berman has served as our chief medical officer since November 2015. From December 2013 to November 2015, he served as president of Biohaven Medical Services LLC and, prior to that, served as a group director of global clinical research at BMS from September 2003 to November 2013. Prior to his time at BMS, Dr. Berman was an associate director of clinical sciences, early development at Pfizer from November 2000 to September 2003. Since October 2012, Dr. Berman has also continued to serve as an adjunct professor of psychiatry at Yale University School of Medicine. Dr. Berman received his B.A. in molecular biophysics and biochemistry from Yale University and his M.D. from Mount Sinai School of Medicine of New York University.

Basic Compensation

Total Annual Compensation, USD 515,729
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 5,331
Fiscal Year Total, USD 521,060

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan

706,360

Vlad Coric

7,854,000

James Engelhart

3,217,070

Kimberly Gentile

2,784,540

Charles Conway

2,792,860

Robert Berman

521,060
As Of  31 Dec 2018